化疗联合CIK免疫治疗对胃癌术后患者的临床疗效

Clinical efficacy of chemotherapy combined with CIK immunotherapy in postoperative patients with gastric cancer

目的分析化疗联合多种细胞因子诱导的杀伤细胞(CIK)免疫治疗对胃癌术后患者的临床疗效。方法选择2010年1月至2013年1月的60例胃癌术后患者为研究对象,随机将其分为对照组和观察组,各30例。对照组给予单纯化疗,观察组给予化疗联合CIK免疫治疗。观察两组临床疗效。结果观察组患者5年后生存率高于对照组(P<0.05)。观察组患者5年随访生存时间显著长于对照组(P<0.05)。观察组CD3^+、CD4^+、CD8^+、CD3^+CD56^+水平明显高于对照组(P<0.05)。结论针对胃癌术后患者,给予化疗联合CIK免疫治疗可以有效提高患者生存率,延长生存时间,同时还可以有效改善患者T细胞亚群,值得临床积极推广。

Objective To analyze the clinical efficacy of chemotherapy combined with cytokine-induced killer （CIK）immunotherapy in postoperative patients with gastric cancer. Methods Sixty postoperative patients with gastric cancer fromJanuary 2010 to January 2013 were selected as research objects and randomly divided into control group and observationgroup, with 30 cases in each group. The control group received chemotherapy alone, while the observation group receivedchemotherapy combined with CIK immunotherapy. The clinical efficacy of the two groups were observed. Results Thesurvival rate after 5 years of the observation group was higher than that of the control group （P〈0.05）. The survival time in5 year follow-up of the observation group was significantly longer than that of the control group （P〈0.05）. The levels of CD3^＋, CD4^＋, CD8^＋and CD3^＋CD56^＋in the observation group were significantly higher than those in the control group （P〈0.05）. Conclusion For postoperative patients with gastric cancer, chemotherapy combined with CIK immunotherapy caneffectively improve the survival rate of patients, prolong survival time and effectively improve the T cell subsets of patients.It＇s worthy of clinical active promotion.